SelectQuote, Inc. (NYSE: SLQT) received a formal non‑compliance notice from the New York Stock Exchange on March 25 2026 for failing to maintain an average closing price of at least $1.00 per share over a consecutive 30‑day period. The notice cites the company’s average closing price of $0.64 on March 24, 2026, as the trigger for the violation.
The NYSE requires listed companies to meet the $1.00 average price threshold and to maintain it for a full calendar month. SelectQuote has a six‑month cure window that ends on September 25, 2026. During this period the company must close at or above $1.00 on the last trading day of any month and sustain an average closing price of $1.00 or more over the preceding 30 trading days. Failure to meet these conditions will result in delisting, which would severely limit liquidity and could lead to a sharp decline in the stock’s value.
SelectQuote’s most recent quarterly results, released on March 24, 2026, showed revenue of $537.1 million, net income of $69.3 million, and adjusted EBITDA of $84.7 million. Earnings per share of $0.26 beat analyst expectations of $0.24 by $0.02, while revenue beat the consensus of $531.93 million by $5.17 million. The earnings beat was driven by strong demand in the Senior segment, which generated $261.5 million in revenue and $102.5 million in adjusted EBITDA, and by a Medicare Advantage season that pushed senior EBITDA margins to 39%.
The company’s three operating segments performed as follows: the Senior segment produced $261.5 million in revenue and $102.5 million in adjusted EBITDA; the Healthcare Services segment generated $230.7 million in revenue but only $0.8 million in adjusted EBITDA, reflecting thin margins in the pharmacy and chronic‑care services; and the Life segment reported $44 million in revenue and $6 million in adjusted EBITDA. The Senior segment’s robust performance offset the weaker Healthcare Services results, allowing the company to post a net income that exceeded expectations.
Management has stated that it will take corrective action to cure the deficiency. The company’s liquidity position remains strong, with a $415 million credit facility that extends most debt maturities to 2031 and an operating cash‑flow outlook of $25 million to $35 million for fiscal 2026. These financial resources provide the flexibility needed to pursue a cure strategy, whether through a reverse split, a capital‑raising event, or other measures permitted under NYSE rules.
The non‑compliance notice signals a significant risk to SelectQuote’s market access and investor confidence. While the company’s recent earnings and liquidity profile suggest it has the resources to address the price deficiency, the potential for delisting remains a material concern that could alter the company’s capital structure and future growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.